forecasted
Improved Drug Susceptibility Testing (DST) for Mycobacteria
National Institutes of Health · RFA-AI-28-018
See source for award amount
Not specified
City or township governments, County governments, Native American tribal governments (Federally recognized), State governments, Independent school districts, For profit organizations other than small businesses, Small businesses, Others (see text field entitled "Additional Information on Eligibility" for clarification), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Public housing authorities/Indian housing authorities, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Private institutions of higher education, Special district governments, Public and State controlled institutions of higher education
Geographic eligibility and all attachment-specific conditions require review of the original announcement.
Eligibility details
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Matching funds & resources
Source matching-funds field: Not Required.
Matching funds and leveraged resources are different requirements. Read the description and reviewed rules below before determining resource commitments.
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Funding geography: Not specified — review source. A funder’s address does not establish eligibility.
Review original source ↗Funding instrument: Cooperative Agreement. Issuing jurisdiction: Federal. This is not a geographic eligibility determination.
Source fields and evidence
id: 362948
Source ↗ · id
opportunityNumber: RFA-AI-28-018
Source ↗ · opportunityNumber
opportunityTitle: Improved Drug Susceptibility Testing (DST) for Mycobacteria
Source ↗ · opportunityTitle
revision: 0
Source ↗ · revision
agencyDetails: {"code":"NIH","seed":"HHS-NIH11","agencyName":"National Institutes of Health","agencyCode":"HHS-NIH11","topAgencyCode":"HHS"}
Source ↗ · agencyDetails
owningAgencyCode: HHS-NIH11
Source ↗ · owningAgencyCode
cfdas: [{"id":434283,"opportunityId":362948,"cfdaNumber":"93.855","programTitle":"Allergy and Infectious Diseases Research"}]
Source ↗ · cfdas
forecastDesc: <p>The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.</p>
Source ↗ · forecastDesc
applicantTypes: [{"id":"02","description":"City or township governments"},{"id":"01","description":"County governments"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"00","description":"State governments"},{"id":"05","description":"Independent school districts"},{"id":"22","description":"For profit organizations other than small businesses"},{"id":"23","description":"Small businesses"},{"id":"25","description":"Others (see text field entitled \"Additional Information on Eligibility\" for clarification)"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"20","description":"Private institutions of higher education"},{"id":"04","description":"Special district governments"},{"id":"06","description":"Public and State controlled institutions of higher education"}]
Source ↗ · applicantTypes
applicantEligibilityDesc: Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Source ↗ · applicantEligibilityDesc
fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments
fundingActivityCategories: [{"id":"HL","description":"Health"}]
Source ↗ · fundingActivityCategories
costSharing: false
Source ↗ · costSharing
lastUpdatedDate: Jun 24, 2026 01:29:59 PM EDT
Source ↗ · lastUpdatedDate
status: forecasted
Source ↗ · oppHits[id=362948].oppStatus
Build your funding pipeline.
Save opportunities, filter by fit, and export your deadlines with membership.
View plans from $49/month ↗